TuHURA Biosciences Inc. (HURA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, HURA scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 5 / 20. Per the Roarable RQD rating, this reflects ROIC of -35% and an FCF yield of -21.1%. For a prospective investor, this means the business is currently consuming cash relative to its capital base; the upside case must rest on future events rather than present cash generation.
• Whale 13F Flow: 11 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. Its mid-range score suggests institutional interest is present but not decisive.
• Insider Conviction: 3 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. The low score indicates weak insider signaling, which a prospective investor should weigh as a lack of visible insider confidence.
• Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, this reflects a beta of 1.0 and sector sensitivity. The stock moves in line with the broader market, offering no defensive cushion.
• Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, this reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 1/9, and Debt/Equity of 0.5. The weak Piotroski reading points to deteriorating financial quality.

Taken together, the rating signals elevated fundamental and balance-sheet risk. Valuation tradeoffs are difficult to assess because earnings-based multiples are unavailable. A prospective investor evaluating the stock today would need to focus on whether the company's pipeline catalysts can justify continued cash burn before the balance sheet tightens further.

Per the SEC financials, the company reported no revenue or operating income across the three periods, with net losses widening from $-15.0M in FY 2023 to $-31.0M in FY 2025. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 1/9. Reported cash declined from $12.7M to $3.6M between FY 2024 and FY 2025, and FCF was $-27.7M in FY 2025, which signals a limited liquidity runway.

Per the recent news feed, the catalysts are patent and clinical-data announcements:

• A new U.S. patent broadening coverage for the VISTA inhibitor TBS-2025.
• A key U.S. patent for the Delta Opioid Receptor antibody drug conjugate technology.
• Initial data from an open-label study of IFx-2.0 with Keytruda in first-line metastatic Merkel cell carcinoma.
• An earnings date and estimates item.

All items are tagged YELLOW with the impact label "MARKET WIRE." Per the Butterfly Supply-Chain Graph, the supply chain is NONE, there are no butterfly links, and there are no proprietary signals. Risk watch items include the cash decline and negative FCF noted in the financial data, and a short-term price move of -6.31% per the market data.

• What is the company's cash runway given the decline from $12.7M to $3.6M and FY 2025 FCF of $-27.7M?
• What is the debt balance, since debt is reported as N/A in every period?
• What outcomes or timelines are associated with the IFx-2.0 Merkel cell carcinoma study and the patent-protected programs?
• Why do the insider and institutional pillars score as they do, and what specific Form 4 or 13F transactions drove those scores?
• What is the company's revenue model, given that reported revenue is $0.0M in every period?